Public biotechs, ranked by BS score.

Pre-revenue biotechs are uniquely falsifiable: their entire valuation rests on whether one drug works. We extract the core hypothesis from SEC filings, score it against trial design quality, historical base-rates, and language red flags, then publish the result.